SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION
First Claim
Patent Images
1. A method for treating a disease or condition in a patient, wherein the method comprises:
- (a) exposing a microbiota in the patient to an antibacterial agent to selectively kill cells of a first species in the microbiota, wherein the first species is a bacterial or archaeal species; and
(b) simultaneously or sequentially administering to the patient an effective amount of a therapy to treat the disease or condition,wherein;
the therapy is selected from the group consisting of an immunotherapy, antibody therapy, adoptive cell therapy, radiation therapy, chemotherapy, and vaccine therapy;
the selective killing is carried out by avoiding killing second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells; and
the proportion of the first cells in the microbiota is thereby reduced to modulate CD8+ immune cells in the patient, whereby the efficacy of the therapy is enhanced for treatment of the disease or condition in the patient.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
-
Citations
20 Claims
-
1. A method for treating a disease or condition in a patient, wherein the method comprises:
-
(a) exposing a microbiota in the patient to an antibacterial agent to selectively kill cells of a first species in the microbiota, wherein the first species is a bacterial or archaeal species; and (b) simultaneously or sequentially administering to the patient an effective amount of a therapy to treat the disease or condition, wherein; the therapy is selected from the group consisting of an immunotherapy, antibody therapy, adoptive cell therapy, radiation therapy, chemotherapy, and vaccine therapy; the selective killing is carried out by avoiding killing second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells; and the proportion of the first cells in the microbiota is thereby reduced to modulate CD8+ immune cells in the patient, whereby the efficacy of the therapy is enhanced for treatment of the disease or condition in the patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification